Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ
13.40
-0.17 (-1.25%)
Closed
Oct 23, 2026
Day's Range
13.2013.61
52 wk Range
12.7925.59
Financial Statements - SNDX - Syndax Pharmaceuticals, Inc.
Revenue
172.35M▲ 627.8%
Net Income
-285.42M▲ 10.5%Net Margin -165.6%
EBITDA
-251.63M▲ 19.8%
Free Cash Flow
-323.16M▼ 17.6%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 172.35M | 23.68M | 0 | 0 | 139.70M | 1.51M |
| Cost of Goods | 6.97M | 826K | - | - | - | - |
| Gross Profit | 165.38M | 22.85M | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -273.08M | -339.67M | -229.95M | -151.75M | 26.22M | -71.42M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -1.28M | -247K | -361K | -316K | 202K | -219K |
| Pre Tax Income | -285.42M | -318.75M | -209.36M | -149.33M | 24.92M | -73.15M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -285.42M | -318.75M | -209.36M | -149.33M | 24.92M | -73.15M |
| EPS Basic | -3.29 | -3.72 | -2.98 | -2.46 | 0.48 | -1.87 |
| EPS Diluted | -3.29 | -3.72 | -2.98 | -2.46 | 0.48 | -1.87 |
| Basic Shares Outstanding | 86.62M | 85.62M | 70.37M | 60.76M | 52.06M | 41.30M |
| Diluted Shares Outstanding | 86.62M | 85.62M | 70.37M | 60.76M | 52.06M | 41.30M |
| Ebit | -251.63M | -313.82M | -209.15M | -146.20M | 26.82M | -70.80M |
| Ebitda | -251.63M | -313.82M | -209.14M | -146.16M | 26.86M | -70.71M |
| Net Income Continuous Operations | -285.42M | -318.75M | -209.36M | -149.33M | 24.92M | -73.15M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | 0 | 0 | 3.90M |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
